— WUSTL Technology 016481
Technology Description
Researchers at Washington University in St. Louis have developed an additional targeting strategy to provide more flexibility and improve the bioactivity of the anticancer therapeutic TR3. This strategy targets TR3 to mesothelin, a tumor biomarker fr…
— WUSTL Technology 011885
Technology Description
Researchers at Washington University in St. Louis have developed a strategy to specifically target the anticancer therapeutic TR3 to cancer cells using the mesothelin/MUC16 interaction. Mesothelin is a GPI linked cell surface protein expressed in mes…
— Technology Description
Researchers from Washington University in St. Louis and colleagues have identified ent-allopregnanolone (ent-AlloP) as a potential therapeutic to treat glaucoma. Glaucoma, the leading cause of irreversible blindness, results from damage to the retinal ganglion cells (RGSs) t…
— Technology Description
Researchers at Washington University in St. Louis have developed a vaccine strategy to prevent catheter-associated urinary tract infections (CAUTIs). CAUTIs are the most common cause of hospital-acquired infections. Many of these are caused by Enterococcus bacteria. CAUTIs a…
— WUSTL Technology 007646
Technology Description
Researchers at Washington University in St. Louis (WUSTL) have developed a novel TRAIL (TNF-related apoptosis inducing ligand)-based anticancer drug platform, designated TR3. TRAIL has potent and specific apoptotic activity against tumor cells. Thus,…
| Name | # Summaries | Author |
|---|---|---|
| 15 | ||
| 13 | ||
| 15 | ||
| 26 | ||
| 14 | ||
| 14 |
Creating...
